Diffuse Lung Disease
-
TETON-1 treatment effects offer hope for patients with idiopathic pulmonary fibrosis
Christopher King, MD, FCCP, and Steven D. Nathan, MD, FCCP, discuss the clinical implications of inhaled treprostinil, including the medication’s potential use in future combination treatment strategies.
-
Positive results from TETON-1 trial introduce potential new therapy for IPF
Positive results from the TETON trials and expanding treatment options are encouraging for pulmonologists who are used to working with a limited toolkit for slowing disease progression in their patients with IPF.
-
Honoring a legacy, empowering the future
The John R. Addrizzo, MD, FCCP, Endowed Research Grant in Sarcoidosis, a transformative and permanent fund dedicated to advancing research in sarcoidosis, is not only a tribute to a beloved husband, father, grandfather, and physician but also a beacon for progress and discovery.
-
Pulmonary rehabilitation in ILD and PH: Expanding access beyond the center
Pulmonary rehabilitation remains one of the most effective interventions available for chronic respiratory disease. The research has shown a need for structured long-term maintenance programs for patients with ILD and PH.
-
Psilocybin-assisted therapy bests nicotine patch for smoking cessation in pilot study
At six months following the target quit date, 40.5% of participants in the psilocybin group achieved biochemically verified prolonged abstinence compared with only 10.0% in the nicotine patch group.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
When oil infrastructure burns: What pulmonary clinicians should know
Recent conflict in the Middle East sheds light on oil fires as respiratory exposure events. Pulmonary clinicians need to be prepared to treat both acute and chronic symptoms from these exposures.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Airway complications post-lung transplant: Risk factors, outcomes, and interventions
Early detection and phenotype-driven bronchoscopic management are key to improving outcomes in patients with airway complications after undergoing lung transplantation.
-
Study links nocturnal GERD, undiagnosed OSA to worse outcomes in IPF
Researchers said the findings support evaluation of sleep‑related comorbidities to identify potentially modifiable contributors to symptoms and physiologic impairment.
-
Local and state options for clean air and climate advocacy
Health care professionals can help drive practical, equitable clean air solutions that protect patients by leveraging their expertise in the clinic, community, and policy arena.
-
Bilateral lung transplant comparable to heart-lung transplant in primary PAH
Recent findings reinforce the widely used strategy of bilateral lung transplantation for most patients with primary PAH who do not have structural heart disease.
